IP Library Granted Patent US 10,034,949
Granted Patent B2
US 10,034,949 · App. 14/409,865 · Granted Jul 31, 2018

Polyvalent pneumococcal polysaccharide-protein conjugate composition

Inventors: Jin-Hwan Shin (Seoul, KR); Ji-Hye Yang (Seoul, KR); Dong-Soo Ham (Suwon-si, KR); Mahn-Hoon Park (Yongin-si, KR); Hun Kim (Suwon-si, KR); Myeong-Ju Noh (Seoul, KR); Su-Jin Park (Seongnam-si, KR); Seon-Young Yang (Incheon, KR)
Assignee: SK CHEMICALS CO., LTD.
A61K47/646A61K39/092A61K39/39A61K47/6415A61K2039/545A61K2039/55505A61K2039/6037A61K2039/70
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,034,949
App. No.
14/409,865
Granted
Jul 31, 2018
Kind
B2
Abstract

Provided is an immunogenic composition comprising 15 different polysaccharide-protein conjugates. Each of the conjugates comprises a capsular polysaccharide prepared from different serotype Streptococcus pneumoniae conjugated to a carrier protein, that is, serotypes 1, 2, 3, 4, 5, 6A, 6B, 7F, 9N, 9V, 14, 18C, 19A, 19F and 23F. An immunogenic composition formulated into a vaccine comprising an aluminum-based adjuvant increases application range with respect to pneumococcal diseases in infants and children.

Claims (28)

1. A multivalent immunogenic composition consisting of 15 distinct capsular polysaccharide-protein conjugates, together with at least one of a physiologically acceptable vehicle and an adjuvant, wherein the capsular polysaccharides are prepared from Streptococcus pneumoniae serotypes 1, 2, 3, 4, 5, 6A, 6B, 7F, 9N, 9V, 14, 18C, 19A, 19F and 23F, and wherein the carrier protein is CRM 197 .

2. The multivalent immunogenic composition of claim 1 , wherein the adjuvant is an aluminum-based adjuvant.

3. The multivalent immunogenic composition of claim 2 , wherein the adjuvant is selected from the group consisting of aluminum phosphate, aluminum sulfate and aluminum hydroxide.

4. The multivalent immunogenic composition of claim 3 , wherein the adjuvant is aluminum phosphate.

5. The multivalent immunogenic composition of claim 1 , which is for inducing an immune response to a Streptococcus pneumoniae capsular polysaccharide conjugate.

6. The multivalent immunogenic composition of claim 5 , wherein the multivalent immunogenic composition is a single 0.5 ml dose formulated to contain:

2 μg of each saccharide, except for 6B at 4 μg;

Approximately 34 μg of the CRM 197 carrier protein;

0.125 mg of elemental aluminum (0.5 mg aluminum phosphate) adjuvant; and

sodium chloride and sodium succinate buffer as excipients.

7. The multivalent immunogenic composition of claim 2 , which is for inducing an immune response to a Streptococcus pneumoniae capsular polysaccharide conjugate.

8. The multivalent immunogenic composition of claim 7 , wherein the multivalent immunogenic composition is a single 0.5 ml dose formulated to contain:

2 μg of each saccharide, except for 6B at 4 μg;

approximately 34 μg of the CRM 197 carrier protein;

0.125 mg of elemental aluminum (0.5 mg aluminum phosphate) adjuvant; and

sodium chloride and sodium succinate buffer as excipients.

9. The multivalent immunogenic composition of claim 3 , which is for inducing an immune response to a Streptococcus pneumoniae capsular polysaccharide conjugate.

10. The multivalent immunogenic composition of claim 9 , wherein the multivalent immunogenic composition is a single 0.5 ml dose formulated to contain:

2 μg of each saccharide, except for 6B at 4 μg;

approximately 34 μg of the CRM 197 carrier protein;

0.125 mg of elemental aluminum (0.5 mg aluminum phosphate) adjuvant; and

sodium chloride and sodium succinate buffer as excipients.

11. The multivalent immunogenic composition of claim 4 , which is for inducing an immune response to a Streptococcus pneumoniae capsular polysaccharide conjugate.

12. The multivalent immunogenic composition of claim 11 , wherein the multivalent immunogenic composition is a single 0.5 ml dose formulated to contain:

2 μg of each saccharide, except for 6B at 4 μg;

approximately 34 μg of the CRM 197 carrier protein;

0.125 mg of elemental aluminum (0.5 mg aluminum phosphate) adjuvant; and

sodium chloride and sodium succinate buffer as excipients.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 27, 2018
From: SK CHEMICALS CO., LTD.
To: SK BIOSCIENCE CO., LTD.
Reel/Frame 046993/0264 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 6, 2018
From: SK DISCOVERY CO., LTD.
To: SK CHEMICALS CO., LTD.
Reel/Frame 046277/0353 →
CHANGE OF NAME Recorded Jun 7, 2018
From: SK CHEMICALS CO., LTD.
To: SK DISCOVERY CO., LTD.
Reel/Frame 046305/0154 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 8, 2015
From: SHIN, JIN-HWAN; YANG, JI-HYE; HAM, DONG-SOO; PARK, MAHN-HOON; KIM, HUN; NOH, MYEONG-JU; PARK, SU-JIN; PARK, SEON-YEONG
To: SK CHEMICAL CO., LTD.
Reel/Frame 035361/0374 →
Priority Claims (1)
KR 10-2012-0065893 · Jun 20, 2012 · national
Continuity (1)
Related Publication 20150190520A1 · Jul 9, 2015
Cited By (1)
US 12,280,107